Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:O76050 (neu)
 3,969 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Brains of small, adult laboratory animals, fixed by formalin-perfusion, and cut into pieces usually 2-3 mm thick X 3-5 mm2 are placed into a solution containing: 7% aqueous solution of potassium dichromate 100 ml, 99.5% ethyl alcohol 40 ml, concentrated formalin 10 ml, distilled water 50 ml, for 24 hours. The process is repeated with a freshly prepared solution for another 24 hours. The pieces are then transferred to a 3.5% aqueous solution of potassium dichromate for 48 hours, and then to a 1% aqueous solution of silver nitrate for 48 hours. Frozen or celloidin sections 70-100 microns in thickness are put into 90% and then into 100% ethyl alcohol for 30 minutes respectively, creosote-benzene (1:1), benzene and mounted with or without cover glass applying Entellan neu. This procedure gives high quality impregnation and it takes about one week to complete.
 ...
PMID:A silver impregnation method for neurons in the central nervous system of the small laboratory animals. 162 May 30

The prognosis for any patient with progressive or recurrent invasive transitional cell carcinoma remains poor. In this context, the focus of clinical research in these invasive cancers concentrates on identifying systemic treatment options and new agents in order to improve survival of patients. Cisplatin-based chemotherapy is standard treatment of patients with metastatic urothelial cancer; however, despite regimens as the cisplatin-gemcitabine combination, the overall response rates vary between 40% and 65%, with complete response in 15%-25% with survivals up to 16 months. This survival is frequently achieved with severe and life-threatening side effects. None the less, almost all responding patients relapse within the first year; therefore, the need for development of new and tolerable agents is urgent. This review highlights some new active chemotherapeutic as new platinum compounds (oxaliplatin, lobaplatin), gallium nitrate, ifosfamide, the antifolates piritrexim and pemetrexed (Alimta, LY231514), vinflunine and molecular targeting agents such as farnesyltransferase inhibitors (lonafarnib, R115777, SCH66336), ribozyme (RPI.4610), histone deacetylase inhibitor (CI-994) and monoclonal antibodies (epidermal growth factor receptor, Her 2/neu).
 ...
PMID:New agents for treatment of advanced transitional cell carcinoma. 1758 53